+ Follow HAL BARRON Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 639200
[Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
[Summary] => TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 628535
[Title] => Roche drug approved as first-line blood cancer maintenance treatment
[Summary] => BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
[DatePublished] => 2010-11-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
HAL BARRON
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 639200
[Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
[Summary] => TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
[DatePublished] => 2010-12-16 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 628535
[Title] => Roche drug approved as first-line blood cancer maintenance treatment
[Summary] => BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
[DatePublished] => 2010-11-11 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
December 16, 2010 - 12:00am
November 11, 2010 - 12:00am